The possibility and prospects of using cytostatics in patients with COVID-19 on the example of cyclophosphamide


如何引用文章

全文:

开放存取 开放存取
受限制的访问 ##reader.subscriptionAccessGranted##
受限制的访问 订阅或者付费存取

详细

Currently, there is no evidence-based data to recommend the use of cyclophosphamide for the treatment of patients with COVID-19. The use of this drug may interfere with the course of SARS-CoV-2 infection, including development of adverse side effects. Clinical trials are required to evaluate the efficacy and safety of cytostatics, including cyclophosphamide, in patients with COVID-19.

全文:

受限制的访问

作者简介

V. Tsvetov

Federal Center for Cardiovascular Surgery

I. Burashnikova

Kazan State Medical Academy - branch of the Russian Medical Academy of Continuous Professional Education

D. Sychev

Russian Medical Academy of Continuous Professional Education

I. Poddubnaya

Russian Medical Academy of Continuous Professional Education

参考

  1. Клиническая фармакология: национальное руководство. Под ред. Ю.Б. Белоусова, В.Г Кукеса, В.К. Лепахина, В.И. Петрова. М., 2009. 976 с. [Clinical pharmacology: national guidelines. Ed. by Yu.B. Belousov, V.G. Kukes, V.K. Lepakhin, VJ. Petrov. M., 2009. 976 p. (In Russ.)].
  2. Cao X. COVID-19: immunopathology and its implications for therapy. Nat Rev Immunol. 2020;20(5):269-70. doi: 10.1038/s41577-020-0308-3.
  3. Misra D.P, Agarwal V, Gasparyan A.Y., Zimba O. Rheumatologists' perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7): 2055-62. doi: 10.1007/s10067-020-05073-9.
  4. Государственный реестр лекарственных средств [Электронный ресурс]. [State Register of Medicines [Electronic resource]. (In Russ.)]. URL: http://grls.rosminzdrav.ru/Grls_View_ v2.aspx?routingGuid=0873b1f1-dc7c-452e-97c4-595469758127&t=.
  5. National Library of Medicine (NLM) [Electronic resource]. URL: https://clinicaltrials.gov/ct_2/ results?term=co vid+or+SARS-CoV-2&cond=Covi d19&intr=Cytostatic#.
  6. EU Clinical Trials Register [Electronic resource]. URL: https://www.clinicaltrialsregister.eu/ctr-search/search?query=Cyclophosphamid&phase =phase-one&phase=phase-two&phase=phase-three&phase=phase-four&dateFrom=2020-01- 01&dateTo=2020-12-23.
  7. Hosoba R., et al. COVID-19 pneumonia in a patient with adult T-cell leukemia-lymphoma. J. Clin Exp Hematopathol. 2020;60(4):174-78. doi: 10.3960/jslrt.20030.
  8. Khurana A., Saxena S. Immunosuppressive agents for dermatological indications in the ongoing COVID 19 pandemic: rationalizing use and clinical applicability. Dermatol Ther. 2020;33(4):e13639. doi: 10.1111/dth.13639.
  9. Al Saleh A.S., et al. Multiple Myeloma in the Time of COVID-19. Acta Haematol. 2020;143(5):410-6. doi: 10.1159/000507690.
  10. Brocato R.L., et al. Disruption of Adaptive Immunity Enhances Disease in SARS-CoV-2-Infected Syrian Hamsters. J. Virol. 2020;94(22):e01683-20. doi: 10.1128/JVI.01683-20.
  11. Revannasiddaiah S., et al. A potential role for cyclophosphamide in the mitigation of acute respiratory distress syndrome among patients with SARS-CoV-2. Med. Hypoth. 2020;144:109850. doi: 10.1016/j.mehy.2020.109850.
  12. El Fakih R., Hashmi S.K., Ciurea S.O., et al. Posttransplant cyclophosphamide use in matched HLA donors: a review of literature and future application. Bone Marrow Transplant. 2020;55:40-7. doi: 10.1038/s41409-019-0547-8.
  13. Mayumi H., Umesue M., Nomoto K. Cyclophosphamide-induced immunological tolerance: an overview. Immunobiol. 1996;195:129-39. doi: 10.1016/S0171-2985(96)80033-7.
  14. Luznik L., O’Donnell P.V., Fuchs E.J. Posttransplantation cyclophosphamide for tolerance induction in HLA-haploidentical bone marrow transplantation. Semin Oncol. 2012;39:683-93.
  15. da Rocha A.P, et al. Covid-19 and patients undergoing pharmacological treatments for immune-mediated inflammatory diseases: protocol for a rapid living systematic review. doi: 10.1101/2020.05.01.20087494.
  16. Harma VK., Khandpur S. Evaluation of cyclophosphamide pulse therapy as an adjuvant to oral corticosteroid in the management of pemphigus vulgaris. Clin Exp Dermatol. 2013;38:659-64. doi: 10.1111/ced.120 73.
  17. Carette S., Klippel J.H., Decker J.L., et al. Controlled studies of oral immunosuppressive drugs in lupus nephritis. A long-term follow-up. Ann Intern Med. 1983;99:1-8. doi: 10.7326/00034819-99-1-1.
  18. Austin H.A., KlippelJ.H., Balow J.E., et al. Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl J Med. 1986;314:614-9. doi: 10.1056/NEJM198603063141004.
  19. De Groot K. Pulse Versus Daily Oral Cyclophosphamide for Induction of Remission in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis. Ann Intern Med. 2009:150(10):670. doi: 10.7326/0003-4819-150-10-200905190 00004.

补充文件

附件文件
动作
1. JATS XML
下载

版权所有 © Bionika Media, 2021
##common.cookie##